انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Episode 29. Management of Peripheral T-Cell Lymphoma
Manage episode 375632193 series 3369804
In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed:
1. “How I Treat Peripheral T-cell Lymphoma?”:
https://pubmed.ncbi.nlm.nih.gov/24615779/
2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34921960/
3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/34843406/
4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/33512419/
5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34653242/
6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:
https://ash.confex.com/ash/2020/webprogram/Paper134650.html
51 حلقات
Manage episode 375632193 series 3369804
In this episode, we discuss the diagnosis and management of peripheral T-cell lymphoma with Dr. Steven Horwitz, with a focus on the 3 most common types-Peripheral T-cell Lymphoma-NOS, Angioimmunoblastic T-cell Lymphoma (AITL), and Anaplastic Large Cell Lymphoma (ALCL). Here are the key papers we discussed:
1. “How I Treat Peripheral T-cell Lymphoma?”:
https://pubmed.ncbi.nlm.nih.gov/24615779/
2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34921960/
3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/34843406/
4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/33512419/
5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34653242/
6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:
https://ash.confex.com/ash/2020/webprogram/Paper134650.html
51 حلقات
Alle episoder
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.